Skip to main content
. 2022 Oct 31;109(4):297–304. doi: 10.1136/heartjnl-2022-321328

Figure 1.

Figure 1

Study design of Rilonacept inHibition of interleukin-1 Alpha and beta for recurrent Pericarditis: a pivotal Symptomatology and Outcomes study (RHAPSODY) run-in period. NSAID, non-steroidal anti-inflammatory drug; SC, subcutaneous.